Agteren, M. van

patient tacrolimu catheter cyp 3a study cyp 3a genotype transplantation group transplant polymorphism cyp 3a expressers genotype concentration mpa auc 0–12 rejection kidney pharmacokinetic exposure incidence cyp 3a nonexpressers transplant recipients crs incidence month citrate mycophenolic acid effect cyp 3a allele difference recipient heparin day 3 allele nonexpresser blood -2152 result -275 0–12 solution table 1000 catheter days analysis mycophenolic infection mpa pharmacokinetics therapy expresser culture –taurolidine dialysis taurolidine mpa exposure ugt 1a tacrolimus dose tacrolimus dose requirement carrier article creatinine clearance dose-adjusted function promoter enzyme pharmacogenetic cyclosporine dose-corrected concentration –time curve mycophenolate mofetil 1 year individual tacrolimus pharmacokinetics target blood culture university mycophenolate tacrolimus c 0 primer mofetil colonization treatment tacrolimus exposure